Cutting Costs in Hospitals: The Value of Combined ESR and CRP Testing Revealed

The Economic Advantages of Dual Laboratory Testing

In the realm of healthcare diagnostics, recent research highlights a compelling argument for retaining both the Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP) tests in clinical settings. Conducted by ALCOR Scientific and published in ClinicoEconomics and Outcomes Research, this peer-reviewed study scrutinizes the interchangeability of these tests and presents significant economic benefits of using both together.

The Financial Implications

With an estimated annual saving of $9.95 million for a typical 739-bed academic medical center, the combined strategy of ESR and CRP testing proves to be financially prudent. By significantly reducing the rates of misdiagnosis, this dual approach mitigates the costs associated with unnecessary follow-ups and additional testing, which often arise from false-positive results typically linked to CRP testing.

Understanding the Complementary Nature of ESR and CRP

Critics of combined testing have long posited that using both ESR and CRP is redundant. However, the authors of the study reveal that these tests serve distinct yet complementary roles. ESR tests reflect changes in the blood associated with inflammation, manifesting slower over a period of 24 to 48 hours, making them particularly effective for identifying chronic inflammatory conditions such as rheumatoid arthritis or lupus.

In contrast, CRP levels spike quickly within hours of acute inflammation but can normalize within days. Thus, utilizing both tests provides a comprehensive diagnostic picture that can enhance clinical decision-making. This depth of information is not achievable by employing a single test alone.

Why This Research Matters Now

The findings come at a crucial time for value-based care, where hospital systems are continually pressured to eliminate seemingly redundant tests to cut costs. Historically, the Choosing Wisely initiative has labeled the ESR test as unnecessary due to its older manual testing methods. However, advancements in automated ESR testing have reduced costs to approximately $2.70 per test, a smaller expense than a cup of coffee. Meanwhile, the CRP test costs around $5.18.

Both tests, when administered together, incur minimal additional expenses yet yield substantial savings from prevented diagnostic errors and their subsequent financial impacts.

Study Design and Results

The researchers employed a decision tree economic model simulating cohorts of 100 patients and assessed the costs from a U.S. healthcare payer perspective across eight different conditions, including rheumatoid arthritis and various cancers. The study leveraged published clinical literature for sensitivity and specificity data and obtained cost metrics from Medicare and Medicaid reimbursement schedules.

Throughout numerous analytical scenarios, the study consistently demonstrated that cutting ESR testing can have the opposite effect - leading to more misdiagnoses and escalated follow-up costs. The automation of ESR testing negates previous resource concerns, establishing it as a cost-effective diagnostic tool.

Conclusion

The evidence strongly underscores that the combined use of ESR and CRP tests not only provides enhanced diagnostic accuracy but also reflects a sound economic strategy for healthcare institutions. By preserving the traditional ESR test alongside CRP, hospitals can prevent unnecessary tests and associated costs, embodying the principles of effective clinical value and decision-making. As healthcare systems aim to optimize resources, understanding the symbiotic relationship between these tests is crucial in fostering better patient outcomes while sustaining fiscal responsibility.

Additional Information

For more insight, the study is available under the citation: Yarnoff B, et al. "Economic Evaluation of Combined Testing Strategies Using Erythrocyte Sedimentation Rate and C-Reactive Protein Tests." ClinicoEconomics and Outcomes Research, 2026; DOI 10.2147/CEOR.S578961.